½ÃÀ庸°í¼­
»óǰÄÚµå
1520405

Ç÷Àü °ü¸® ±â±â ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Clot Management Devices Market Report by Product Type, End-User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 18¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ 2024³âºÎÅÍ 2032³â±îÁö 4.8%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀ̸ç, 2032³â¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Ç÷Àü °ü¸® ±â±â´Â Æó »öÀüÁõ(PE), µ¿¸Æ Ç÷Àü, ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõ(DVT)°ú °°Àº Ä¡·á¿¡ »ç¿ëµÇ´Â ÀÇ·á±â±â¸¦ ÀǹÌÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â Ç÷Àü °ü¸® ±â±â´Â Ä«Å×ÅÍ Á÷Á¢ Ç÷Àü ¿ëÇØ ¿ä¹ý(CDT) ±â±â, »öÀü Á¦°Å dz¼± Ä«Å×ÅÍ, °æÇÇÀû Ç÷Àü Á¦°Å ±â±â, ½Å°æÇ÷°ü »öÀü Á¦°Å ±â±â, ÇÏ´ë Á¤¸Æ ÇÊÅÍ(IVCF) µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ÀåÄ¡´Â ȯÀÚÀÇ ½ÉÀå, ³ú, Æó, ´Ù¸®¿¡¼­ Ç÷ÀüÀÇ ¹ß»ýÀ» ¾ïÁ¦Çϰí ÇãÇ÷¼º ³úÁ¹Áß, ½ÉÇÑ ´Ù¸® ÅëÁõ, ½ÉÀå ¹ßÀÛÀÇ ¹ß»ýÀ» ¿¹¹æÇÕ´Ï´Ù.

¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀå µ¿Çâ :

½ÉÇ÷°ü Áúȯ(CVDs)ÀÇ À¯º´·ü Áõ°¡´Â ¼¼°è ³ëÀÎ Àα¸ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. ¾É±â½¬¿î ¶óÀÌÇÁ ½ºÅ¸Àϰú °Ç°­¿¡ ÇØ·Î¿î ½Ä»ýȰ·Î ÀÎÇØ ½ÉÀå Áúȯ°ú DVT, PE¿¡ ½Ã´Þ¸®´Â »ç¶÷µéÀÌ ´Ã¾î³ª°í Ç÷Àü °ü¸® ±â±â ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ȯÀÚ¿Í °Ç°­ °ü¸® Á¦°ø¾÷ü ¸ðµÎ Àúħ½À(MI) Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ±â°èÀû Ç÷Àü Á¦°Å¼úÀº ¿Ü°úÀǻ簡 ÀÛÀº Àý°³¸¦ ÅëÇØ ȯÀÚÀÇ µ¿¸Æ¿¡¼­ Ç÷ÀüÀ» Á¦°ÅÇϱâ À§ÇØ Æ¯¼ö Àåºñ¸¦ »ç¿ëÇÏ´Â MI Ä¡·áÀÔ´Ï´Ù. À̿ʹ º°µµ·Î, Ä«Å×ÅÍ Áö½Ã Ç÷Àü ¿ëÇØ ¿ä¹ýÀÌ ÇÊ¿äÇÑ °í°üÀý, ¹«¸­, ôÃß ¼Õ»óÀÇ »ç·Ê°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â Â÷¼¼´ë Ç÷ÀüÁ¦°ÅÀåÄ¡ÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼úÀÇ Áøº¸, ºñ¿ë È¿À²ÀûÀÎ ÀåÄ¡ÀÇ Áö¼ÓÀûÀÎ Ãâ½Ã, ÀÇ·á°úÇÐ ºÐ¾ß¿¡¼­ÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ÀÖ½À´Ï´Ù., ½ÃÀåÀ» ´õ °ßÀÎ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ÃßÀÌÇØ, ÇâÈÄ ¾î¶»°Ô ÃßÀÌÇØ °¥ °ÍÀΰ¡?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº ¾îµðÀԴϱî?
  • ¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀå¿¡ ÁØ COVID-19ÀÇ ¿µÇâÀº?
  • Á¦Ç° À¯Çüº° ½ÃÀå ºÐ¼®Àº ¹«¾ùÀΰ¡?
  • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº ¹«¾ùÀΰ¡?
  • Ç÷Àü °ü¸® ±â±â ½ÃÀå »ê¾÷ÀÇ ¹ë·ùüÀÎÀÇ ´Ù¾çÇÑ ´Ü°è´Â?
  • ¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀåÀÇ ±¸Á¶ ¹× ÁÖ¿ä ±â¾÷Àº?
  • »ê¾÷¿¡¼­ÀÇ °æÀïµµ¶õ?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ç÷Àü °ü¸® ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼®: Á¦Ç° À¯Çüº°

  • ½Å°æÇ÷°ü »öÀü Á¦°Å ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »öÀü Á¦°Å dz¼± Ä«Å×ÅÍ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °æÇÇ Ç÷Àü Á¦°Å ±â±â
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä À¯Çü
      • ±â°èÀû Ç÷Àü Á¦°Å¼ú
      • ÈíÀÔ Ç÷Àü Á¦°Å¼ú
      • °æÇÇÀû ±â°èÀû Ç÷Àü Á¦°Å¼ú(PMT)
    • ½ÃÀå ¿¹Ãø
  • Ä«Å×ÅÍ À¯µµ Ç÷Àü ¿ëÇØ ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÇÏ´ëÁ¤¸ÆÇÊÅÍ
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä À¯Çü
      • ¿µ±¸
      • ÀϽà À¯Ä¡
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áø´Ü¼¾ÅÍ ¹× Àü¹® Ŭ¸®´Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ÁöÇ¥

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • AngioDynamics Inc.
    • Argon Medical Devices Inc.
    • Boston Scientific Corporation
    • DePuy Synthes Inc.
    • Edwards Lifesciences Corporation
    • iVascular SLU
    • Lemaitre Vascular Inc.
    • Medtronic Inc.
    • Straub Medical AG
    • Stryker Corporation
    • Teleflex Incorporated
    • Vascular Solutions
AJY 24.08.19

The global clot management devices market size reached US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.

Clot management devices refer to the medical equipment that are used for the treatment of ailments such as pulmonary embolism (PE), arterial blood clots and deep vein thrombosis (DVT). Some of the commonly used clot management devices include catheter-directed thrombolysis (CDT) devices, embolectomy balloon catheters, percutaneous thrombectomy devices, neurovascular embolectomy devices and inferior vena cava filters (IVCFs). These devices aid in inhibiting the development of blood clots in the heart, brain, lungs and legs of the patient, thereby preventing the instances of potential ischemic strokes, severe leg pain and heart attacks.

Global Clot Management Devices Market Trends:

The increasing prevalence of cardiovascular diseases (CVDs), along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Owing to the sedentary lifestyles and unhealthy dietary habits, a greater number of individuals are suffering from heart ailments, DVT and PE, thereby enhancing the demand for clot management devices. Furthermore, the growing preference for minimally invasive (MI) procedures by both patients and healthcare providers is also boosting the market growth. For instance, mechanical thrombectomy is an MI procedure in which the surgeon uses specialized equipment to remove the clot from the patient's artery through a small incision. Apart from this, the increasing instances of hip, knee and spinal injuries that require catheter-directed thrombolysis, have also created a positive impact on the market growth. Other factors, including various technological advancements, such as the development of next-generation thrombectomy devices, the continual launch of cost-effective devices, along with extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global clot management devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type and end-user.

Breakup by Product Type:

Neurovascular Embolectomy Devices

Embolectomy Balloon Catheters

Percutaneous Thrombectomy Devices

Mechanical Thrombectomy

Aspiration Thrombectomy

Percutaneous Mechanical Thrombectomy (PMT)

Catheter-Directed Thrombolysis Devices

Inferior Vena Cava Filters

Permanent

Retrievable

Breakup by End-User:

Hospitals

Diagnostic Centers and Specialty Clinics

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AngioDynamics Inc., Argon Medical Devices Inc., Boston Scientific Corporation, DePuy Synthes Inc., Edwards Lifesciences Corporation, iVascular S.L.U., Lemaitre Vascular Inc., Medtronic Inc., Straub Medical AG, Stryker Corporation, Teleflex Incorporated, Vascular Solutions, etc.

Key Questions Answered in This Report:

  • How has the global clot management devices market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global clot management devices market?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global clot management devices market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Clot Management Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Neurovascular Embolectomy Devices
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Embolectomy Balloon Catheters
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Percutaneous Thrombectomy Devices
    • 6.3.1 Market Trends
    • 6.3.2 Major Types
      • 6.3.2.1 Mechanical Thrombectomy
      • 6.3.2.2 Aspiration Thrombectomy
      • 6.3.2.3 Percutaneous Mechanical Thrombectomy (PMT)
    • 6.3.3 Market Forecast
  • 6.4 Catheter-Directed Thrombolysis Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Inferior Vena Cava Filters
    • 6.5.1 Market Trends
    • 6.5.2 Major Types
      • 6.5.2.1 Permanent
      • 6.5.2.2 Retrievable
    • 6.5.3 Market Forecast

7 Market Breakup by End-User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diagnostic Centers and Specialty Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Indicators

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AngioDynamics Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Argon Medical Devices Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Boston Scientific Corporation
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 DePuy Synthes Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Edwards Lifesciences Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 iVascular S.L.U.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Lemaitre Vascular Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Medtronic Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Straub Medical AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Stryker Corporation
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Teleflex Incorporated
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Vascular Solutions
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦